Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia.
Ying ZhangYan WangMieke L Van DrielTreasure M McGuireTao ZhangYuzhu DongYang LiuLeichao LiuRuifang HaoLu CaoJianfeng XingYa-Lin DongPublished in: Antimicrobial resistance and infection control (2019)
In these clinical trials, considering efficacy, safety, and cost-effectivenes, linezolid and tedizolid showed their superiority in MRSA cSSSI; while linezolid might be recommended to treat MRSA pneumonia. Although vancomycin was not cost-effective in pharmacoeconomic evaluation, it is still the first-line treatment for MRSA infection in the clinical practice. This study might provide new insights of therapeutic choices for patients with MRSA infections whilst awaiting the arrival of higher quality evidence.
Keyphrases
- methicillin resistant staphylococcus aureus
- staphylococcus aureus
- systematic review
- clinical trial
- clinical practice
- healthcare
- emergency department
- meta analyses
- randomized controlled trial
- quality improvement
- intensive care unit
- wound healing
- electronic health record
- mechanical ventilation
- phase iii
- placebo controlled